Lung Cancer

Neoadjuvant nivolumab in combination with platinum-doublet chemotherapy significantly improved pathological complete response rates and had a greater depth of pathological response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.

Adjuvant treatment with gefitinib delayed early relapse in patients with completely resected EGFR-mutant non–small cell lung cancer. However, the EGFR inhibitor did not significantly improve disease-free survival or overall survival compared with cisplatin/vinorelbine.

OncLive sits down with Edward S. Kim, MD, and Anthony R. Mato, MD, on the pivotal studies in lung cancer and leukemia at the 2021 ASCO Annual Meeting.

In a final overall survival analysis of the J-ALEX study, patients with non-small cell lung cancer receiving alectinib failed to achieve better results than patients receiving crizotinib.

Treatment with selpercatinib demonstrated consistent efficacy in patients with RET fusion-positive non-small cell lung cancer, regardless of prior treatments.

Treatment with aumolertinib was associated with prolonged survival and duration of response in patients with non–small cell lung cancer.

Amivantamab in combination with lazertinib elicited responses in more than one-third of chemotherapy-naïve patients with EGFR-mutant non–small cell lung cancer who had progressed on osimertinib.

Patritumab deruxtecan was found to induce clinically meaningful, durable efficacy in heavily pretreated patients with EGFR-mutated non–small cell lung cancer who were resistant to EGFR TKIs.

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the results of subgroup analysis from the phase 2 CodeBreaK 100 trial in patients with KRAS G12C-mutant non–small cell lung cancer.

Martin Reck, MD, PhD, discusses updated results of the phase 3 CheckMate 9LA study in advanced non–small cell lung cancer.

Nivolumab and ipilimumab plus 2 cycles of platinum-based chemotherapy demonstrated durable survival benefit vs chemotherapy alone in patients with advanced non–small cell lung cancer.

CLN-081 demonstrated promising preliminary antitumor activity and an acceptable safety profile across all doses tested in patients with previously treated non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.

Data from an updated analysis of the phase 3 PACIFIC trial indicate that treatment with durvalumab after chemoradiotherapy is associated with long-term survival improvements in patients with unresectable stage III non-small cell lung cancer.

The combination of nivolumab and ipilimumab continued to provide a durable, long-term overall survival benefit compared with chemotherapy after 4 years for patients with advanced non‒small cell lung cancer regardless of PD-L1 expression or histology.

Mobocertinib, a first-in-class, oral, EGFR TKI, induced rapid, deep, and durable responses and a manageable safety profile in patients with platinum-pretreated EGFR exon 20 insertion–positive metastatic non–small cell lung cancer.

Pembrolizumab plus concurrent chemoradiation therapy induced antitumor effects in patients with unresectable, locally advanced, stage III non–small cell lung cancer irrespective of PD-L1 expression or tumor histology.

Brigatinib demonstrated sustained long-term responses and survival in patients with crizotinib-refractory ALK-positive non–small cell lung cancer.

Updated findings from the ARROW trial demonstrated that pralsetinib could benefit those with RET fusion–positive non–small cell lung cancer and is a well-tolerated agent in the patient population.

Christian Grohé, MD, and Gary Doherty, MRCP, PhD, consider factors that may influence the resectability of patients with stage IIIA-N2 disease, such as biomarker status, performance status, and imaging results.

A panel of experts in the management of lung cancer share key insights into challenges associated with retesting for driver mutations, tumor heterogeneity, and potential differences between biopsy and surgical sample test results.

Rogerio C. Lilenbaum, MD, discusses the clinical implications of the FDA approval of lurbinectedin in metastatic small cell lung cancer.

The European Commission has approved the dual immunotherapy combination of nivolumab and ipilimumab for use in the frontline treatment of adults with unresectable malignant pleural mesothelioma.

Helen J. Ross, MD, discusses toxicity concerns with combinations therapies in EGFR-mutant non–small cell lung cancer.

The FDA has approved sotorasib as the first treatment for adult patients with non–small cell lung cancer whose tumors harbor KRAS G12C mutations and who have received at least 1 prior systemic therapy.

Novel immunotherapy combinations are gaining ground in the frontline treatment of patients with lung cancer, but the toxicities associated with these regimens must be weighed against the benefit they provide.